Medication info

Acytamet Tablet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›505mg / 1 tablet
Manufacturer / importer
Anguk Pharmaceutical Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 202200203 · Approved 2022.01.11

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of this medicine 50/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined taking into account the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Anguk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty controlling blood sugar
View approved original text

This medication helps to control blood sugar levels in patients with type 2 diabetes and assists dietary and exercise therapies. It can be used alone for patients starting diabetes medication for the first time. If blood sugar control is difficult with metformin or sitagliptin monotherapy, this medication can be used as a replacement or in combination. Additionally, if blood sugar control is insufficient after combination therapy with metformin and sulfonylurea, or metformin and thiazolidinedione, this medication is added as a supplementary treatment. This medication can also be added for improved blood sugar control if the effectiveness is inadequate with insulin and metformin therapy. In summary, this medication is used to enhance blood sugar control at various treatment stages for patients with type 2 diabetes.

How to take

Adult dose

In antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of this medicine 50/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined taking into account the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication contains both sitagliptin and metformin for diabetes treatment. Firstly, sitagliptin can rarely cause serious allergic reactions, so patients should be cautious of symptoms of hypersensitivity during the first three months. Additionally, there is a risk of developing a serious pancreatic disease called pancreatitis, so if symptoms such as abdominal pain or vomiting occur, patients should consult a doctor immediately. Metformin can result in lactic acidosis, a rare but fatal metabolic complication, thus it should not be administered to patients with reduced kidney function or liver disease. Specifically, it should not be used in cases of acute kidney failure, dehydration, severe infections, or cardiovascular issues. This medication is not to be administered to children under 18 years of age or to pregnant or nursing women. For the elderly, dosage adjustment and regular kidney function monitoring are necessary due to potentially decreased kidney function. Patients should be vigilant for hypoglycemia symptoms during treatment, especially when taken with other hypoglycemic agents or insulin, as the risk of hypoglycemia may increase. Moreover, excessive alcohol intake might elevate the risk of lactic acidosis and should be avoided. Before and after examinations using iodine-based contrast agents, this medication should be temporarily discontinued, and it should be resumed only after confirming normal kidney function. For patients undergoing surgery, the medication should be halted 48 hours before surgery and can be restarted once kidney function has recovered post-surgery. While taking this medication, it is advisable to have regular checks of blood sugar, kidney function, liver function, and hematological tests, and to monitor vitamin B12 levels. If symptoms such as skin rashes, hives, difficulty breathing, severe abdominal pain, vomiting, severe joint pain, or blistering skin conditions appear, patients should inform their doctor immediately. This medication may interact with other drugs, so it is crucial to inform healthcare providers of any other medications being taken, especially those that could affect kidney function. Finally, it is essential to maintain a balanced diet and exercise routine while taking this medication, along with consistent monitoring of blood sugar and physical condition.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 21 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and debilitating arthralgia
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • dermatitis
  • anorexia
  • weight loss
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • decreased appetite
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air ingress and should be kept at a temperature between 1 and 30 degrees Celsius. This will help maintain its efficacy and prevent degradation.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.